Female Reproductive & Breast

Postmenopausal bleeding: workup and management

Clinical Overview and When to Suspect Endometrial Pathology

— Endometrial cancer is the most common gynecologic malignancy in the US; 90% present with abnormal bleeding, making PMB a "red flag until proven otherwise."

— Obesity (peripheral aromatization), nulliparity, late menopause (>55), early menarche (<12), chronic anovulation/PCOS history, diabetes, tamoxifen use, unopposed estrogen therapy, Lynch syndrome (40–60% lifetime endometrial cancer risk).

— Age >60, BMI >30, diabetes, recurrent or persistent bleeding, tamoxifen, family history of Lynch (colon/endometrial/ovarian).

— Endometrial/vaginal atrophy (most common, ~60–80%), endometrial or cervical polyps, submucosal fibroids, endometrial hyperplasia without atypia, infection (cervicitis, endometritis), trauma, anticoagulant effect, HRT breakthrough bleeding.

Definition: Postmenopausal bleeding (PMB) = any uterine bleeding ≥12 months after the last menstrual period in a woman not on cyclic hormone therapy, or unscheduled bleeding on continuous combined HRT after the first 6 months.

Why it matters: PMB is the cardinal symptom of endometrial cancer — ~9–10% of women with PMB have endometrial carcinoma, and another 5–15% have complex/atypical hyperplasia (a precursor lesion).

Epidemiology drivers (unopposed estrogen exposure):

When to suspect malignancy specifically:

Common benign etiologies (still must be excluded by workup, not assumed):

Step 3 management: Every episode of PMB requires evaluation — there is no threshold of "minimal" bleeding that can be observed. A single spotting episode in a 65-year-old warrants the same workup as recurrent bleeding.

Board pearl: Bleeding on tamoxifen is never to be attributed to drug effect alone — tamoxifen increases endometrial cancer risk 2–7×, and these patients need tissue sampling, not just imaging (subepithelial cystic changes can falsely thicken endometrial stripe on TVUS).

Presentation Patterns and Key History

— Onset relative to menopause date (confirm 12 consecutive months of amenorrhea before the index bleed).

— Quantity (spotting vs frank bleeding, pads/hour), duration, recurrence, postcoital component.

— Associated discharge (foul → infection or necrotic tumor), pelvic pain, pressure, urinary/bowel symptoms (advanced disease).

— Systemic or vaginal estrogen, continuous combined vs sequential HRT (sequential = expected withdrawal bleed; continuous = should be amenorrheic after 6 months).

— Tamoxifen (breast cancer survivors), aromatase inhibitors (typically don't cause bleeding — investigate harder).

— Anticoagulants/antiplatelets, herbal estrogens (black cohosh, soy isoflavones, phytoestrogens).

— SSRIs and antipsychotics rarely cause endometrial changes but may cause platelet dysfunction.

— Obesity, T2DM, HTN ("endometrial cancer triad"), nulliparity, chronic anovulation, PCOS, late menopause, prior breast/ovarian/colon cancer, Lynch syndrome family history (≥3 relatives with Lynch-associated cancers, 2 generations, 1 under 50 — Amsterdam II).

— Hematuria mistaken for vaginal bleeding (UTI, bladder cancer) — ask about timing with urination.

— Rectal bleeding (hemorrhoids, colorectal cancer) — ask about bowel movements, blood mixed with stool.

— Vulvar/vaginal lesions, postcoital bleeding (cervical pathology).

Bleeding characteristics to elicit:

Hormonal/medication history (high yield):

Risk factor inventory:

Source-of-bleeding clues (must localize):

Constitutional symptoms: Weight loss, early satiety, abdominal distension (suggest advanced gyn malignancy or ovarian primary).

Key distinction: Sequential HRT users expect a monthly withdrawal bleed and only require workup if the pattern changes (heavier, prolonged, intermenstrual). Continuous combined HRT users should be amenorrheic after 6 months — any bleed after that window is treated as PMB and worked up fully.

Board pearl: Always document the exact date of menopause and current/prior hormone regimens — exam stems hinge on whether bleeding is "expected" or pathologic.

Physical Exam Findings and Hemodynamic Assessment

— Tachycardia, orthostasis, or hypotension is uncommon in PMB but mandates IV access, CBC, type and screen, and resuscitation before proceeding to outpatient workup.

— Pallor + heavy bleeding → admit, transfuse if Hgb <7 (or <8 with cardiac disease per AABB).

— Vulva: lichen sclerosus (white atrophic plaques), vulvar intraepithelial neoplasia, vulvar carcinoma (ulcer, mass), urethral caruncle (red friable lesion at meatus — common mimic).

— Vagina: atrophic changes (pale, thin, loss of rugae, petechiae), trauma, foreign body (pessary erosion is classic), vaginal cancer.

— Speculum: visualize cervix — polyps, friability, mass, contact bleeding; obtain cervical cytology if not up to date and biopsy any visible lesion regardless of stripe thickness.

— Bimanual: uterine size (enlarged → fibroids, sarcoma, advanced cancer), adnexal mass (ovarian primary or metastasis), parametrial nodularity (cervical or endometrial cancer extension).

— Rectovaginal: posterior cul-de-sac nodularity, rectal source of bleeding.

Vital signs first:

General exam: BMI (obesity = ongoing estrogen exposure), acanthosis nigricans (insulin resistance), thyromegaly (thyroid disease can cause AUB even postmenopausally), supraclavicular/inguinal lymphadenopathy (metastatic disease).

Abdominal exam: Palpable pelvic/abdominal mass, ascites (advanced endometrial or ovarian cancer), hepatomegaly.

Pelvic exam — systematic from outside in:

CCS pearl: On the CCS, in a hemodynamically stable PMB patient, the correct first move after history is pelvic exam with speculum and bimanual — ordering TVUS or biopsy before exam loses points because you must first localize the source (cervical vs uterine vs vaginal vs non-gyn).

Board pearl: A urethral caruncle and atrophic vaginitis together cause ~30% of PMB and can be diagnosed on exam alone — but you still need TVUS or sampling to rule out concurrent endometrial pathology because two diagnoses can coexist.

Diagnostic Workup — Initial Labs and Imaging

— CBC (anemia severity), type and screen if heavy or recurrent bleeding.

— Coagulation panel (PT/INR, aPTT) if on anticoagulants or bleeding history; CMP for renal/hepatic baseline before procedures.

— Pregnancy test is NOT indicated if menopause is confirmed (12 months amenorrhea + age-appropriate); include it in perimenopausal patients with ambiguous LMP.

— TSH if symptoms suggest thyroid dysfunction.

— Cervical cytology + HPV co-test if not current per ASCCP (women 65+ may exit screening only if adequate prior negative screening; otherwise update).

— Measures endometrial stripe (double-layer thickness) in sagittal plane.

— ≤4 mm with PMB: Endometrial cancer risk <1% — high negative predictive value (~99%). Reasonable to observe if bleeding resolves; recurrent or persistent bleeding still mandates tissue sampling regardless of thin stripe.

— >4 mm: Endometrial sampling required.

— Indeterminate stripe (cannot adequately visualize, heterogeneous, fibroid distortion): proceed directly to sampling or saline infusion sonography (SIS).

— Focal lesions (polyp, submucosal fibroid) → SIS or hysteroscopy preferred over blind biopsy.

— Adnexal mass → evaluate per ovarian cancer pathway (CA-125, RMI, GYN-onc referral).

Laboratory studies:

First-line imaging — Transvaginal ultrasound (TVUS):

TVUS additional findings:

Key distinction: The 4 mm cutoff applies to bleeding postmenopausal women. In asymptomatic women, a thickened endometrium (even up to 11 mm) does NOT mandate biopsy if no bleeding — incidental findings are managed differently. Never apply screening logic to symptomatic patients and vice versa.

Board pearl: TVUS measurement is unreliable in tamoxifen users (subepithelial cysts inflate the stripe); these patients should proceed to hysteroscopy with directed biopsy as the initial test rather than relying on stripe thickness.

Diagnostic Workup — Advanced or Confirmatory Studies

— First-line tissue sampling: ~90–98% sensitive for endometrial cancer when diffuse, lower for focal lesions.

— Indications: stripe >4 mm, recurrent/persistent PMB regardless of stripe, tamoxifen use, Lynch syndrome, high clinical suspicion.

— Inadequate or insufficient samples (common in atrophy or stenotic os) require further evaluation, not reassurance — proceed to hysteroscopy + D&C.

— Distends uterine cavity to characterize focal lesions (polyps, submucosal fibroids) missed on TVUS.

— Helpful before operative hysteroscopy planning.

— Contraindicated in active pelvic infection or suspected pregnancy.

— Gold standard when blind biopsy is non-diagnostic, when focal lesions exist, or in tamoxifen users.

— Allows direct visualization, targeted sampling, and simultaneous polypectomy/myomectomy.

— If cervical lesion visible or cytology abnormal: colposcopy + cervical biopsy + endocervical curettage.

— MRI pelvis: assess myometrial invasion and cervical involvement (gold standard for local staging).

— CT chest/abdomen/pelvis: evaluate nodal and distant disease.

— CA-125: elevated in advanced/serous endometrial cancers; aids in surveillance.

— Universal Lynch syndrome screening (MMR IHC: MLH1, MSH2, MSH6, PMS2) on all endometrial cancer specimens regardless of age — analogous to colorectal cancer protocol.

Endometrial biopsy (Pipelle/office aspiration):

Saline infusion sonography (SIS / sonohysterography):

Hysteroscopy with directed biopsy and D&C:

Cervical evaluation:

Imaging for staging (after malignancy diagnosed):

Genetic testing:

Step 3 management: If office biopsy returns "insufficient tissue" or "scant atrophic endometrium" in a patient with persistent PMB, do not stop — proceed to hysteroscopy with D&C. Up to 10% of cancers are missed by Pipelle, particularly polypoid or focal disease.

Board pearl: "Complex atypical hyperplasia" on biopsy is associated with concurrent endometrial carcinoma in ~40% of hysterectomy specimens — counsel accordingly and refer to GYN oncology.

Risk Stratification and First-Line Management Logic

— Stripe ≤4 mm + single bleeding episode + clear atrophic cause: Observe; treat atrophy; sample if bleeding recurs.

— Stripe ≤4 mm + recurrent/persistent bleeding: Proceed to biopsy or hysteroscopy.

— Stripe >4 mm or focal lesion: Endometrial biopsy ± SIS/hysteroscopy.

— Visible cervical/vaginal lesion: Biopsy that lesion directly (don't bypass it for TVUS).

— Atrophic endometrium / proliferative / secretory: Benign — treat underlying cause (atrophy, polyp, HRT adjustment).

— Endometrial polyp: Hysteroscopic polypectomy (malignancy in ~3–5% of postmenopausal polyps, higher with tamoxifen).

— Hyperplasia without atypia: Progestin therapy (oral medroxyprogesterone, micronized progesterone, or levonorgestrel IUD) with repeat sampling at 3–6 months; total regression ~80%.

— Atypical hyperplasia (EIN): Total hysterectomy is standard; progestin therapy (LNG-IUD) only for fertility preservation (not applicable in postmenopausal) or surgical contraindication.

— Endometrial carcinoma: Refer to GYN oncology for staging and surgery.

— Cardiopulmonary clearance, anticoagulation bridging, DVT prophylaxis planning.

— Preoperative anemia correction (IV iron if Hgb <10 and surgery within 4 weeks).

Decision pathway after exam + TVUS:

Risk-stratified biopsy results:

Surgical risk assessment:

Step 3 management: A postmenopausal woman with atypical hyperplasia who is a poor surgical candidate (severe cardiac disease, morbid obesity precluding anesthesia) can be managed with levonorgestrel IUD + endometrial surveillance every 3–6 months — but this is second-line and requires explicit shared decision-making about the ~40% concurrent cancer risk.

Board pearl: Postmenopausal endometrial polyps have a higher malignancy risk than premenopausal polyps; all symptomatic postmenopausal polyps should be removed, not just observed.

Pharmacotherapy — First-Line Regimens for Benign and Premalignant Causes

— Vaginal estrogen: estradiol cream (0.5 g 2–3×/week after 2-week loading), estradiol tablets (10 mcg twice weekly), conjugated estrogen cream, or estradiol ring (every 3 months).

— Minimal systemic absorption — does NOT require concurrent progestin in women without a uterus, AND per ACOG/NAMS, low-dose vaginal estrogen does not require progestin even with intact uterus for short-term use, though some experts recommend surveillance.

— Contraindications: Active estrogen-sensitive cancer (breast, endometrial) — use non-hormonal moisturizers, lubricants, or ospemifene (SERM) or DHEA (prasterone) vaginal inserts. Consult oncology for breast cancer survivors before any estrogen.

— Levonorgestrel-releasing IUD (Mirena) — first-line per ACOG/RCOG, regression ~90%.

— Oral medroxyprogesterone acetate 10–20 mg daily, or micronized progesterone 200 mg daily continuous.

— Megestrol acetate 40–160 mg daily for refractory cases.

— Repeat biopsy at 3 and 6 months; if regression sustained, surveillance every 6–12 months.

— First 6 months of continuous combined HRT: often resolves; reassure after excluding pathology.

— Persistent: switch regimen, increase progestin component, or discontinue HRT after evaluation.

— No effective medical therapy — hysteroscopic resection is definitive.

— Not standard for PMB; reserved for heavy bleeding awaiting definitive procedure.

Atrophic vaginitis/endometritis (most common benign cause):

Endometrial hyperplasia without atypia:

HRT-related breakthrough bleeding:

Polyp management adjunct:

Antifibrinolytics (tranexamic acid):

Key distinction: Atypical hyperplasia is NOT a medical-therapy disease in postmenopausal women — surgery (hysterectomy + BSO) is standard. Medical therapy with high-dose progestins or LNG-IUD is reserved for those who cannot undergo surgery or (in younger women) desire fertility preservation.

Board pearl: Tamoxifen-associated bleeding rarely responds to medical therapy — these patients need hysteroscopic evaluation; do not simply switch to an aromatase inhibitor without tissue diagnosis.

Procedures and Surgical Management

— Indicated for: insufficient office biopsy, focal lesions on TVUS/SIS, recurrent PMB despite negative blind sampling, tamoxifen users.

— Allows polypectomy, targeted biopsy of suspicious areas, removal of submucosal fibroids.

— Risks: uterine perforation (~1%), infection, fluid overload with hypotonic distension media, cervical injury.

— Hysteroscopic resection is standard; all specimens to pathology (3–5% malignancy in postmenopausal polyps).

— Atypical endometrial hyperplasia (EIN): Total hysterectomy + bilateral salpingo-oophorectomy (BSO) standard in postmenopausal women.

— Endometrial carcinoma: Total hysterectomy + BSO + pelvic/para-aortic lymphadenectomy (or sentinel node biopsy) — performed by gynecologic oncology.

— Refractory hyperplasia without atypia after medical therapy failure.

— Large symptomatic fibroids causing PMB.

— Stage I: confined to uterus; IA <50% myometrial invasion, IB ≥50%.

— Stage II: cervical stromal invasion.

— Stage III: local/regional spread (adnexa, vagina, lymph nodes).

— Stage IV: bladder/bowel mucosa or distant metastasis.

— Low-risk Stage IA grade 1–2 endometrioid: surgery alone.

— Intermediate risk: vaginal brachytherapy.

— High-intermediate/high risk: external beam RT ± chemotherapy (carboplatin + paclitaxel).

— Advanced/recurrent: chemotherapy ± immunotherapy (pembrolizumab for MSI-high/dMMR), hormonal therapy for ER+ low-grade.

Hysteroscopy with D&C (diagnostic + therapeutic):

Endometrial polypectomy:

Hysterectomy indications in PMB:

Endometrial cancer staging (surgical, FIGO 2023):

Adjuvant therapy by stage and risk:

CCS pearl: When ordering hysterectomy for endometrial cancer on CCS, the correct consult is gynecologic oncology, not general gynecology — staging lymphadenectomy and surgical expertise affect survival. Move location to inpatient/OR, then post-op floor, with VTE prophylaxis ordered.

Board pearl: Sentinel lymph node mapping with indocyanine green has largely replaced full lymphadenectomy for apparent uterine-confined disease, reducing lymphedema risk while preserving staging accuracy.

Special Populations — Elderly, Renal, and Hepatic Considerations

— Higher likelihood of malignancy at presentation (age is independent risk factor).

— Cervical stenosis is common — office biopsy often fails; lower threshold for hysteroscopy under anesthesia.

— Comorbidities (CAD, CHF, COPD) affect surgical candidacy — preoperative cardiac risk stratification (RCRI, ACS-NSQIP calculator), pulmonary optimization.

— Frailty assessment (Clinical Frailty Scale, gait speed) predicts perioperative morbidity better than age alone.

— Minimally invasive (laparoscopic or robotic) hysterectomy preferred — reduced blood loss, shorter LOS, faster recovery vs open.

— Vaginal hysterectomy is appropriate for early-stage disease in frail patients without adnexal pathology.

— Avoid NSAIDs for procedural pain control (worsens AKI risk).

— Adjust gabapentin and opioid dosing for renal clearance.

— Carboplatin (if chemotherapy needed) dosed via Calvert formula using GFR.

— Contrast-enhanced staging imaging: hold metformin around contrast; ensure adequate hydration; gadolinium contraindicated if eGFR <30.

— Coagulopathy assessment before any biopsy or surgery — correct INR with vitamin K or FFP if >1.5 and procedure planned.

— Avoid hepatically metabolized progestins at high doses; LNG-IUD is hepatically safe (low systemic exposure).

— Tamoxifen contraindicated in active liver disease.

— Bridging vs holding depends on indication (mechanical valve, recent VTE, CHA2DS2-VASc).

— Hold DOACs 24–48 h before biopsy/hysteroscopy; warfarin held 5 days with bridging if high thromboembolic risk.

— Resume per ACCP guidelines based on bleeding risk of procedure.

Elderly (>75) considerations:

Anesthesia and surgical modifications:

Renal impairment (CKD):

Hepatic impairment:

Anticoagulated patients:

Step 3 management: In a 78-year-old with PMB, dementia, and ASA IV status, vaginal hysterectomy or LNG-IUD with surveillance may be more appropriate than aggressive staging surgery — engage palliative care and family in goals-of-care discussion early.

Board pearl: Postmenopausal patients on chronic warfarin who bleed don't get to "skip" workup because of anticoagulation — supratherapeutic INR does not explain PMB and full evaluation is mandatory.

Special Populations — Breast Cancer Survivors, Lynch Syndrome, HRT Users

— Tamoxifen doubles to septuples endometrial cancer risk; any PMB requires hysteroscopy + biopsy (TVUS stripe is unreliable).

— Switch to aromatase inhibitor (anastrozole, letrozole) in postmenopausal women only after gyn-onc consultation if endometrial pathology found.

— Vaginal estrogen for atrophic symptoms is controversial; ASCO permits low-dose vaginal estrogen in women on tamoxifen with refractory symptoms after non-hormonal options fail, but avoid in women on aromatase inhibitors (systemic absorption could blunt AI efficacy) — coordinate with oncology.

— Non-hormonal alternatives: vaginal moisturizers, lubricants, ospemifene (avoid in active breast cancer), prasterone (DHEA, limited data).

— 40–60% lifetime risk of endometrial cancer; often presents at younger age but PMB workup is mandatory.

— Surveillance: annual endometrial biopsy and TVUS starting age 30–35.

— Risk-reducing hysterectomy + BSO recommended after childbearing complete (typically age 40–45).

— Universal MMR testing on all endometrial cancers identifies probands.

— Sequential HRT: withdrawal bleed expected — investigate only if pattern changes.

— Continuous combined: should be amenorrheic after 6 months — any bleed thereafter = full PMB workup.

— Estrogen-only HRT in a woman with a uterus is malpractice (massive endometrial cancer risk) — always pair with progestin.

— Highest endometrial cancer risk; counsel on weight loss as adjuvant (bariatric surgery reduces endometrial cancer incidence ~60%).

— Minimally invasive hysterectomy preferred; specialized OR positioning and equipment.

Breast cancer survivors:

Lynch syndrome (HNPCC):

HRT users:

Obesity (BMI ≥40):

Pregnancy: Not applicable in confirmed postmenopause; perimenopausal patients with bleeding require pregnancy test before invasive workup.

Key distinction: Lynch syndrome endometrial cancer often presents in the lower uterine segment and may be missed by routine fundal biopsy — hysteroscopic visualization is preferred in known carriers.

Board pearl: Every endometrial cancer specimen in the US now undergoes universal MMR/MSI testing — a positive result triggers germline testing and cascade screening of relatives for colorectal/ovarian/urothelial cancers.

Complications and Adverse Outcomes

— Progression of hyperplasia to carcinoma (atypical hyperplasia → cancer in ~30% within 5 years if untreated).

— Advanced-stage endometrial cancer at diagnosis (Stage III/IV 5-year survival 47–17% vs Stage I ~95%).

— Chronic anemia, fatigue, reduced quality of life.

— Endometrial biopsy: Vasovagal reaction, cramping, infection (<1%), uterine perforation (<0.1%).

— Hysteroscopy: Perforation (~1%), fluid overload (hypotonic media → hyponatremia, cerebral edema; isotonic saline preferred), gas embolism (rare with CO2), infection, cervical laceration.

— D&C: Asherman syndrome (intrauterine adhesions — less concerning postmenopausally as fertility not an issue), perforation.

— Bleeding, infection (vaginal cuff cellulitis, abscess), ureteral injury (0.5–1%), bladder/bowel injury, VTE, vaginal cuff dehiscence.

— Surgical menopause symptoms if oophorectomy (already postmenopausal so minimal).

— Pelvic floor dysfunction, vaginal shortening, dyspareunia.

— Acute: cystitis, proctitis, vaginal mucositis.

— Late: vaginal stenosis (use vaginal dilators), radiation-induced bladder/bowel injury, secondary malignancy, lymphedema.

— Neuropathy, myelosuppression, alopecia, hypersensitivity reactions, nephrotoxicity.

— Progestin therapy: weight gain, mood changes, VTE risk (especially with high-dose megestrol).

— Tamoxifen for ER+ disease: thromboembolism, hot flashes, paradoxical endometrial stimulation.

Complications of untreated/delayed diagnosis:

Procedural complications:

Hysterectomy complications:

Radiation therapy complications:

Chemotherapy toxicities (carboplatin/paclitaxel):

Hormonal therapy complications:

Step 3 management: Post-hysterectomy patients require VTE prophylaxis with enoxaparin for 28 days if surgery was for malignancy (extended prophylaxis per ACCP), versus 7–10 days for benign indications. Don't shortchange this on the CCS.

Board pearl: Vaginal cuff dehiscence classically presents 6–8 weeks post-hysterectomy with sudden gush of fluid or bowel evisceration after intercourse — surgical emergency requiring immediate OR.

When to Escalate Care — Triage and Consultation

— Hemodynamic instability (HR >110, SBP <90, orthostasis) → IV access, fluids, transfusion, urgent gyn consult, possible exam under anesthesia.

— Hgb <7 (or <8 with cardiac comorbidity) → transfuse.

— Suspected uterine perforation with peritoneal signs.

— Sepsis from infected uterine pathology (endometritis with pyometra in elderly) → IV antibiotics, drainage.

— Visible cervical or vaginal mass — biopsy by gyn.

— Biopsy showing hyperplasia (any type) or carcinoma.

— Recurrent PMB despite negative initial workup.

— Inability to perform office biopsy (stenotic os, patient intolerance).

— Any endometrial carcinoma — definitive surgery and staging.

— Atypical endometrial hyperplasia (EIN) — concurrent cancer risk ~40%.

— Suspicious adnexal mass on imaging.

— High-grade or serous histology requires upfront gyn-onc management.

— Recurrent or metastatic disease.

— Medical oncology for chemotherapy planning.

— Radiation oncology for adjuvant or palliative RT.

— Genetic counseling for Lynch-positive tumors.

— Palliative care for advanced/metastatic disease — early referral improves QOL and may improve survival.

— Stable PMB with benign workup (atrophy, polyp scheduled for elective resection).

— Hyperplasia without atypia on progestin therapy with reliable follow-up.

Emergency department / inpatient admission:

Urgent (within 1–2 weeks) gynecology referral:

Gynecologic oncology referral mandatory for:

Multidisciplinary involvement:

Outpatient management appropriate for:

CCS pearl: A 70-year-old with PMB, Hgb 6.8, and known anticoagulation should be admitted, transfused, anticoagulation reversed (or held), gyn consulted, and biopsy done inpatient — do not discharge for outpatient workup.

Board pearl: Pyometra (pus in the uterine cavity) in postmenopausal women is associated with underlying endometrial or cervical malignancy in up to 50% of cases — drainage alone is insufficient; tissue sampling is mandatory once infection controlled.

Key Differentials — Gynecologic Causes

— Thin, friable endometrium with surface erosions; TVUS stripe typically ≤4 mm.

— Treatment: vaginal estrogen, moisturizers.

— Focal echogenic lesion on TVUS, well-defined on SIS, often vascular pedicle on Doppler.

— Malignancy in 3–5% postmenopausally — hysteroscopic resection.

— Hypoechoic intracavitary mass distorting endometrium; SIS clarifies.

— Less common cause of PMB but possible with degeneration or surface erosion.

— Thickened endometrium, often >8 mm; histologic diagnosis.

— Without atypia: progestin therapy.

— With atypia (EIN): hysterectomy.

— Most often endometrioid (Type I, estrogen-driven, low grade, good prognosis).

— Type II (serous, clear cell, carcinosarcoma): not estrogen-driven, older patients, poorer prognosis, p53 mutations.

— Cervical polyp, cervicitis, cervical carcinoma (especially in unscreened women), cervical ectropion (less common postmenopausally).

— Atrophic vaginitis (most common), vaginal cancer (HPV-related), foreign body (pessary erosion), trauma.

— Lichen sclerosus, vulvar intraepithelial neoplasia, vulvar carcinoma (mass, ulceration, induration — biopsy any persistent lesion).

— Estrogen-secreting tumors (granulosa cell tumors) cause endometrial hyperplasia and PMB — workup with TVUS, CA-125, inhibin B.

— Ovarian cancer with vaginal metastasis or hormone production.

— Rare, aggressive; rapidly enlarging uterus with PMB; leiomyosarcoma, endometrial stromal sarcoma, carcinosarcoma (MMMT).

— MRI helps distinguish from benign fibroids (irregular margins, central necrosis, diffusion restriction).

Endometrial atrophy (60–80% of PMB):

Endometrial polyp:

Submucosal fibroid:

Endometrial hyperplasia (with or without atypia):

Endometrial carcinoma:

Cervical causes:

Vaginal causes:

Vulvar causes:

Adnexal/ovarian causes:

Uterine sarcoma:

Key distinction: Type I endometrioid cancer is estrogen-driven, lower-grade, better prognosis, and presents earlier due to bleeding. Type II (serous, clear cell) is non–estrogen-driven, p53-mutated, presents at higher stage with worse prognosis, even when stripe appears thin — clinical suspicion drives evaluation.

Board pearl: A granulosa cell tumor classically presents with PMB + an adnexal mass + elevated inhibin B — don't forget to look at the ovaries on TVUS.

Key Differentials — Non-Gynecologic Causes of "Vaginal" Bleeding

— Hematuria from UTI, urolithiasis, bladder cancer (especially in smokers, age >55, painless gross hematuria).

— Urethral caruncle: red, friable polypoid lesion at urethral meatus — common in postmenopausal women, treat with topical estrogen ± excision.

— Urethral diverticulum, urethral prolapse.

— Hemorrhoids (bright red blood on toilet paper, perianal).

— Anal fissure (pain + bleeding with defecation).

— Colorectal cancer (mixed blood and stool, change in bowel habits, weight loss) — colonoscopy if any suspicion.

— Rectovaginal fistula (from radiation, surgery, Crohn disease, malignancy) — feces or gas per vagina.

— Coagulopathy (warfarin, DOACs, antiplatelet therapy, liver disease, thrombocytopenia, acquired vWD).

— Always review medications and consider iatrogenic etiology, but do not attribute PMB solely to anticoagulation without ruling out structural pathology.

— Pessary erosion (most common in long-term pessary users without follow-up).

— Sexual trauma, abuse — consider in vulnerable adults.

— Recent gynecologic procedures, IUD-related bleeding, missed HRT doses leading to withdrawal bleed.

— Phytoestrogens, herbal supplements with estrogenic activity (black cohosh, red clover).

— Severe hypothyroidism can cause AUB even in postmenopausal women — check TSH if clinical signs.

— Adrenal/ovarian androgen-secreting tumors rarely cause bleeding via aromatization.

Urinary tract sources (commonly mistaken for vaginal bleeding):

Gastrointestinal sources:

Hematologic / systemic causes:

Trauma / foreign body:

Iatrogenic / medication-induced:

Endocrine causes:

Key distinction: A 72-year-old with painless gross hematuria mistaken for PMB needs cystoscopy and CT urogram for bladder cancer evaluation — failing to localize the source is a high-yield clinical error.

Step 3 management: When localization is unclear, place a tampon and observe — vaginal source soils the tampon; urinary/rectal sources stain the perineum or pad pattern. Visualize urine and stool independently.

Board pearl: Mandatory reporting of suspected elder abuse applies if exam findings (vaginal trauma without explanation, multiple unexplained injuries, neglect) suggest abuse — protocols vary by state but obligation is universal.

Secondary Prevention and Long-Term Plan

— Continue vaginal estrogen as needed for symptomatic atrophy.

— Counsel patient to report any recurrent bleeding immediately — recurrence warrants repeat workup.

— Address modifiable risk factors: weight loss, glycemic control, blood pressure management.

— Repeat endometrial biopsy at 3 and 6 months; if regression, continue therapy with biopsy at 6–12 month intervals.

— Consider transition to LNG-IUD if not already in place.

— After 12 months of sustained regression, individualized surveillance.

— Surveillance every 3–6 months for first 2 years, then every 6–12 months for 3 years, then annually.

— Physical and pelvic exam at each visit; vaginal cytology not routinely recommended.

— Imaging (CT, MRI) only if symptoms suggest recurrence.

— CA-125 if elevated at diagnosis.

— Generally avoid systemic estrogen replacement in survivors of high-grade or advanced disease.

— Low-risk (Stage I, grade 1–2 endometrioid): estrogen replacement may be considered after 6–12 months disease-free with gyn-onc input.

— Vaginal estrogen for atrophic symptoms is generally acceptable in low-risk disease.

— Weight loss (5–10% reduces endometrial cancer recurrence risk).

— Physical activity (150 min/week moderate intensity).

— Diabetes and hypertension control.

— Smoking cessation (reduces overall cancer mortality).

— Postmenopausal women, especially after BSO or on aromatase inhibitors: DEXA scan, calcium/vitamin D, weight-bearing exercise; bisphosphonates per FRAX score.

After benign workup (atrophy, treated polyp):

After hyperplasia without atypia (on progestin therapy):

After atypical hyperplasia or carcinoma (post-hysterectomy):

Hormone therapy after endometrial cancer:

Lifestyle and risk reduction:

Bone health:

Step 3 management: Endometrial cancer survivors should be on a structured surveillance schedule with their gyn-oncologist — primary care reinforces lifestyle modification, manages comorbidities, and is the first to hear about new symptoms. Coordinate care actively.

Board pearl: ~80% of endometrial cancer recurrences occur within 3 years; vaginal recurrence is most common and often salvageable with radiation — prompt evaluation of any new vaginal bleeding post-treatment is critical.

Follow-Up, Monitoring, and Counseling

— Benign workup, atrophy treated: routine annual visit; return precautions.

— Polyp removed (benign): no specific surveillance unless recurrent.

— Hyperplasia without atypia: repeat biopsy 3 and 6 months on therapy; then 6–12 months.

— Post-hysterectomy for benign disease: routine well-woman care.

— Years 1–2: every 3–6 months — history, physical, pelvic exam.

— Years 3–5: every 6–12 months.

— After year 5: annually.

— Patient education: report vaginal bleeding, pelvic/abdominal pain, leg swelling (DVT or lymphedema), persistent cough (lung metastasis), unexplained weight loss.

— Reassure that most PMB is benign but evaluation is essential.

— Explain the 4 mm TVUS threshold and why biopsy may still be needed.

— Discuss the link between obesity, diabetes, and endometrial cancer — motivate lifestyle change.

— For Lynch carriers: cascade testing for relatives, surveillance for other Lynch-associated cancers (colonoscopy every 1–2 years from age 20–25, urinalysis annually, dermatologic exam).

— Address dyspareunia, vaginal dryness, body image post-hysterectomy.

— Vaginal dilators after pelvic radiation to prevent stenosis.

— Pelvic floor physical therapy for post-surgical dysfunction.

— Cancer diagnosis triggers depression/anxiety in ~25% — screen with PHQ-9, GAD-7; refer to oncology social work or psychiatry.

— Support groups, survivorship programs.

— Influenza, COVID-19, pneumococcal, shingles, RSV per age recommendations.

— Maintain screening for other cancers: mammography, colonoscopy, lung CT if eligible.

Follow-up cadence after initial PMB workup:

Surveillance after endometrial cancer (NCCN):

Counseling content:

Sexual health and quality of life:

Psychosocial support:

Vaccinations and preventive care:

CCS pearl: Always advance the clock and bring the patient back for the scheduled repeat biopsy at 3 months for hyperplasia without atypia — missing surveillance is a common CCS pitfall.

Board pearl: Tamoxifen-treated breast cancer patients do NOT need routine endometrial biopsy or TVUS surveillance in the absence of bleeding — surveillance only with symptoms; counsel patients to report any bleeding.

Ethical, Legal, and Patient Safety Considerations

— Postmenopausal women generally accept hysterectomy more readily than premenopausal, but body image, sexuality, and identity issues remain — explore patient values.

— For atypical hyperplasia: explicitly disclose the ~40% concurrent cancer risk — patients who decline surgery must understand the implications.

— Document discussion of alternatives (LNG-IUD), risks (bleeding, infection, ureteral injury 0.5–1%, vaginal cuff dehiscence), and benefits.

— Patients with cognitive impairment: assess capacity; involve healthcare proxy; document.

— For elderly or frail patients: discuss goals of care, life expectancy, and treatment tolerance.

— A 90-year-old with low-grade Stage IA endometrial cancer and severe dementia may reasonably forgo surgery in favor of palliative hormonal therapy.

— Lynch-positive endometrial cancer triggers obligation to inform relatives — clinician counsels patient but cannot directly disclose to relatives without consent (HIPAA, duty to warn varies by state).

— Genetic counseling referral is standard before and after testing.

— Suspected elder abuse or neglect (genital trauma, malnutrition, unexplained injuries) — most US states mandate reporting to Adult Protective Services.

— Suspected intimate partner violence in older adults remains underdetected; screen routinely.

— Post-discharge after hysterectomy: ensure clear instructions on activity restriction (no heavy lifting, no intercourse for 6 weeks to prevent cuff dehiscence), wound care, medication reconciliation, follow-up appointment scheduled.

— Medication reconciliation: stop tamoxifen if endometrial cancer found (after oncology discussion), restart anticoagulation per protocol, address bowel regimen for opioid prescriptions.

— Discharge bridge: confirm patient has transportation, caregiver support, understanding of red flags (fever, heavy bleeding, leg pain, shortness of breath).

— Endometrial cancer mortality is higher in Black women, partly due to delayed diagnosis and higher rates of aggressive histologies (serous) — equitable access to TVUS, biopsy, and gyn-onc referral matters.

Informed consent for hysterectomy:

Shared decision-making:

Genetic testing and family implications:

Mandatory reporting:

Transition-of-care safety:

Equity and access:

Step 3 management: When a patient with atypical hyperplasia declines hysterectomy, document the refusal, capacity assessment, alternative plan (LNG-IUD + surveillance), and reassessment timeline — protects against future litigation and ensures continuity.

Board pearl: Failure to evaluate PMB is a leading cause of gynecologic malpractice claims — "wait and see" is never the answer.

High-Yield Associations and Rapid-Fire Facts

— 10% of PMB = endometrial cancer; 60–80% = atrophy.

— Endometrial cancer = most common gynecologic malignancy in the US.

— 90% of endometrial cancers present with bleeding — early detection is feasible.

— ≤4 mm → cancer risk <1% (symptomatic patients).

— Asymptomatic thickened endometrium → no biopsy unless bleeding develops.

— Tamoxifen users → TVUS unreliable, go to hysteroscopy.

— Estrogen unopposed, Nulliparity, Diabetes, Obesity, Menopause late, Early menarche, Tamoxifen, Radiation prior, Infertility/anovulation, Age >50, Lynch syndrome.

— Combined oral contraceptives (40–50% risk reduction), multiparity, smoking (modestly protective for endometrial cancer — DO NOT recommend!), physical activity.

— Type I (endometrioid, 80%): estrogen-driven, PTEN/KRAS mutations, better prognosis.

— Type II (serous, clear cell, carcinosarcoma): p53 mutations, aggressive, older women.

— IA <50% myometrium, IB ≥50%; II cervical stroma; III local spread; IV bladder/bowel/distant.

— Stage I ~95%, Stage II ~75%, Stage III ~50%, Stage IV ~17%.

— Granulosa cell tumor → estrogen → endometrial hyperplasia/PMB + inhibin B elevation.

— Lynch syndrome → MMR mutations (MLH1, MSH2, MSH6, PMS2) → colorectal + endometrial + ovarian + urothelial cancers.

— Cowden syndrome (PTEN) → endometrial cancer + breast cancer + thyroid cancer.

— PCOS history → chronic anovulation → long-term endometrial cancer risk even after menopause.

— Without atypia → progestin (LNG-IUD first-line).

— With atypia (EIN) → hysterectomy + BSO (standard postmenopausally).

PMB epidemiology snapshot:

TVUS thresholds:

Risk factor mnemonic — "ENDOMETRIAL":

Protective factors:

Histologic types:

Staging essentials (FIGO):

5-year survival:

Key associations:

Treatments by hyperplasia type:

Board pearl: Pembrolizumab (anti-PD-1) is FDA-approved for MSI-high/dMMR endometrial cancer — Lynch-associated tumors respond particularly well; immunotherapy is now first-line for advanced dMMR disease.

Key distinction: Postmenopausal vaginal bleeding may originate from urethra, vagina, cervix, uterus, or rectum — localize the source before pursuing one workup pathway.

Board Question Stem Patterns

Classic stem 1: 62-year-old obese diabetic woman with 2 weeks of vaginal spotting, BMI 38, last menstrual period 10 years ago. TVUS shows endometrial stripe 9 mm. → Next step: endometrial biopsy. Wrong answers include "repeat TVUS in 3 months" and "vaginal estrogen trial."

Classic stem 2: 70-year-old on tamoxifen 5 years for breast cancer presents with PMB. TVUS shows stripe of 6 mm with cystic changes. → Next step: hysteroscopy with directed biopsy (TVUS unreliable on tamoxifen). Wrong answer: "endometrial biopsy in office" (likely to miss focal lesion).

Classic stem 3: 58-year-old with PMB. Office Pipelle returns "scant atrophic endometrium." Bleeding continues. → Next step: hysteroscopy with D&C (don't accept inadequate sample when bleeding persists).

Classic stem 4: 65-year-old with PMB; biopsy shows "complex atypical hyperplasia." → Next step: total hysterectomy with bilateral salpingo-oophorectomy (concurrent cancer risk ~40%; progestin is wrong answer in postmenopausal patient).

Classic stem 5: 67-year-old with PMB; biopsy shows endometrial adenocarcinoma, endometrioid type, grade 1. → Next step: refer to gynecologic oncology (not general gyn) for staging surgery.

Classic stem 6: 55-year-old with PMB and unilateral 6-cm adnexal mass, TVUS shows endometrial stripe 12 mm. → Consider estrogen-secreting tumor (granulosa cell) — order inhibin B, full workup including endometrial biopsy and surgical evaluation.

Classic stem 7: 72-year-old whose endometrial cancer specimen shows loss of MSH2 on IHC. → Refer for germline genetic testing for Lynch syndrome; cascade screening for family.

Classic stem 8: 68-year-old on continuous combined HRT for 3 years presents with new spotting. → Evaluate as PMB (after 6 months continuous combined, should be amenorrheic): pelvic exam + TVUS.

Classic stem 9: 80-year-old with dementia, ASA IV, atypical hyperplasia on biopsy, family declines surgery. → LNG-IUD insertion + surveillance biopsy at 3 and 6 months; document goals of care.

Classic stem 10: Post-hysterectomy patient 7 weeks out presents with sudden gush of fluid and bowel protrusion after intercourse. → Vaginal cuff dehiscence — surgical emergency.

CCS pearl: On CCS, the highest-yield orders for PMB are: pelvic exam, TVUS pelvis, CBC, endometrial biopsy — in that sequence, advancing the clock realistically between each.

One-Line Recap

Postmenopausal bleeding is endometrial cancer until proven otherwise — every episode requires evaluation with pelvic exam and TVUS, with endometrial biopsy mandatory for stripe >4 mm, recurrent bleeding, or any tamoxifen user, because timely workup catches endometrioid cancer at curable Stage I.

— Pelvic exam + TVUS first (localize source, measure stripe).

— Stripe >4 mm OR recurrent bleeding OR tamoxifen → tissue sampling.

— Inadequate Pipelle in persistently bleeding patient → hysteroscopy + D&C.

— Atrophy → vaginal estrogen.

— Polyp → hysteroscopic resection (all sent to pathology).

— Hyperplasia without atypia → LNG-IUD or oral progestin; repeat biopsy at 3 and 6 months.

— Atypical hyperplasia (EIN) in postmenopausal → hysterectomy + BSO (40% concurrent cancer).

— Endometrial carcinoma → gynecologic oncology referral for staging surgery; universal MMR testing.

— Don't observe a thin stripe if bleeding recurs.

— Don't trust TVUS in tamoxifen users.

— Don't attribute PMB to anticoagulation alone.

— Don't skip pelvic exam — localize source (urethral caruncle, rectal bleeding, vaginal cancer are mimics).

— Don't forget Lynch screening on every endometrial cancer.

Workup essentials:

Management essentials:

High-yield pitfalls to avoid:

Step 3 management: Coordinate gyn-onc referral, extended VTE prophylaxis post-cancer surgery, genetic counseling for Lynch, and structured surveillance every 3–6 months for 2 years; counsel survivors on red flags and reinforce weight, glycemic, and blood pressure control to reduce recurrence and improve overall survival.

Board pearl: The single most tested concept is that a thin endometrial stripe does not eliminate the need for biopsy in a patient with persistent or recurrent PMB — clinical suspicion overrides reassuring imaging.